Cell Culture – News and Features

This divestment allows Morphotek to focus its business strategy on advancing its therapeutic antibody pipeline.

ATCC's non-exclusive licensing program ensures equitable access to reference research materials.

Chromos will use its ACE System to develop a cell line for a Pfizer therapeutic protein product candidate.

ATCC's non-exclusive licensing program ensures equitable access to reference research materials.

Sangamo will use its ZFP technology to develop cell lines for enhanced protein production.

Integration of both companies’ product will enables BioPharma companies to develop excellence in their manufacturing processes.

Acceptys has acquired the right to develop all 8 lead antibody therapeutic candidates from the OncoMab pipeline.

Researchers develop a technique to attach therapeutic genes to a stent's bare metal surface.

The 3rd Annual Biologicals Manufacturing conference draws on the experience of several biotechs from across Europe and will deliver case studies of their experiences in this field.

Qiagen will develop world’s largest collection of validated siRNAs through an extensive validation project.